Clinical trials: Current Smokers
- Condition Current Smokers
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy
Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
The primary and secondary objectives of the current study are the assessments of anti-inflammatory pharmacodynamic effects on segmental endotoxin induced inflammatory response after 4 weeks treatment with BI 1026706.
- Trial name
- NCT02657408
- Testing
- BI 1026706
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Smoking, Exercise Capacity
Effect of Switching From Cigarette Smoking to IQOS on Exercise Capacity
This exploratory study is part of the global clinical assessment program of IQOS. It was designed to provide scientific evidence to further substantiate the reduced risk potential of using a heated tobacco product (the Tobacco…
- Trial name
- NCT03887117
- Testing
- IQOS + Exercise Training Program, IQOS without Exercise Training Program, Cigarette Smoking + Exercise Training Program
- Where
- Germany
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking, Tobacco Use
CSD210904: Study to Assess Actual Use of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in Current Adult Smokers
This is a multi-site, open-label, 8-week, prospective observational study, conducted at multiple sites geographically dispersed within the U.S. The purpose of this Actual Use Study (AUS) is to investigate how U.S.
- Conditions
- Smoking, Tobacco Use, Tobacco Smoking
- Trial name
- NCT05102786
- Testing
- 40007388, 40007385, 40007387
- Where
- 10 sites in United States
- Volunteers
- 1,180 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking, Tobacco
CSD201204 An Actual Use Study of P12 Electronic Nicotine Delivery System Among U.S. Adult Smokers
The purpose of this Actual Use Study (AUS) is to investigate how United States (US) adult tobacco consumers 21 to 60 years of age, inclusive, who are regular smokers (≥5 cigarettes/day on at least 20 of the past 30 days) will use…
- Trial name
- NCT05960305
- Testing
- P1213416, P1213422, P1213716
- Where
- 12 sites in United States
- Volunteers
- 1,845 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Respiratory Disorders
A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine
The purpose of this study is to test two different vaccine schedules to be used for administering the investigational NTHi Mcat vaccine that will be targeting patients with chronic obstructive pulmonary disease (COPD) to prevent…
- Trial name
- NCT03443427
- Testing
- NTHi Mcat investigational vaccine (GSK3277511A)
- Where
- 8 sites in Canada, Germany and 1 more
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
DNA Damage
Effect of Noni Juice on Lipid Peroxidation-derived DNA Adducts in Heavy Smokers
The purpose of this study was to determine if noni juice reduces lipid hydroperoxide (LOOH) and malondialdehyde (MDA) derived-DNA adducts, markers of oxidative DNA damage, in peripheral blood lymphocytes of cigarette smokers.
- Trial name
- NCT01677169
- Testing
- Noni juice
- Where
- United States
- Volunteers
- 317 people, healthy volunteers welcome
- Sponsor
- Tahitian Noni International, Inc.
Current Smokers
Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)
Proof of concept: Superiority of Bronchipret or Sinupret to placebo in respect to mucociliary clearance
- Trial name
- NCT01928901
- Testing
- administration of Sinupret, administration of Bronchipret
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bionorica SE
Cigarette Smoking
Nicotine Pharmacokinetics From Research Electronic Nicotine Delivery System S-TA-U001 in Smokers and E-Cigarette Users
To better understand the PK and associated pharmacodynamic (PD) responses produced by the Research ENDS S-TA-U001 product, this study will compare the Research ENDS S-TA-U001 to The subject's own brand combustion (non-menthol)…
- Trial name
- NCT02792426
- Testing
- Research ENDS S-TA-U001, Nicorette Inhalator
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- NJOY, Inc.
Respiratory Disorders
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of 8 different formulations of investigational NTHI vaccine in current and former smokers, 50-70 years of age.
- Trial name
- NCT01678677
- Testing
- NTHI vaccine GSK2838500A (formulation 1), NTHI vaccine GSK2838501A (formulation 2), NTHI vaccine GSK2838502A (formulation 3)
- Where
- 3 sites in Belgium
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Smoking, Tobacco
A Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers
The goal of this study is to evaluate the rate of end of study complete cigarette reduction in health adult consumers of cigarettes when given access to a heated tobacco product (HTP).
- Trial name
- NCT07710820
- Testing
- 31237616, 31237617, 31237571
- Where
- 9 sites in United States
- Volunteers
- 1,060 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
COPD
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
Chronic obstructive pulmonary disease (COPD) is a common inflammatory disease of the airway affecting approximately 10% of individuals aged 40 years or more with a smoking history.
- Trial name
- NCT01780298
- Where
- United Kingdom
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Tobacco Use Disorder
A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers
The purpose of this study is to assess the bioequivalence of the 21mg nicotine transdermal patch from GSK Dungarvan (Test) compared to the 21mg nicotine transdermal patch currently manufactured by Alza (Reference).
- Trial name
- NCT05024747
- Testing
- NicoDerm CQ patch (GSK Dungarvan), NicoDerm CQ (Alza)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- HALEON
Nicotine
Nicotine Pharmacokinetics and Pharmacodynamics of Two Variants of VM 1.0 Compared to Cigarettes in Adult Current Smokers
A single-center, randomized, controlled, partially blinded, crossover study to evaluate the pharmacokinetics and pharmacodynamics of nicotine following use of two variants of VM 1.0, VM16 and VM32, a nicotine-containing aerosol…
- Trial name
- NCT07135648
- Testing
- VM16, VM32, Cigarette (CC)
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.